GGrantIndex
← Leaderboards

Melissa Caroline Skala

Morgridge Institute For Research, Inc.

$12,296,713
Attributed
$18,379,934
Total exposure
15
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY200725
$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,379,934 · 15

By mechanism

R01$13,150,637 · 6
U01$3,055,117 · 3
R21$1,248,547 · 3
R00$727,316 · 1
F32$109,721 · 1
K99$88,596 · 1

Top collaborators

Others in their field

Top investigators on “Image

Research focus

ImageResponseOpticsIn VivoTechnologyCellsMetabolicMalignant NeoplasmsTumorPharmaceutical PreparationsMetabolic ImagingMonitor3-DimensionalDrug DevelopmentResolutionFluorescenceLabelOrganoidsDrug ResistanceMetabolismMouse ModelNeoplastic CellGoldStructure

Grant awards (45)

Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$663,363
R01 · FY2025 · CA · contact PI
Label-free imaging of CAR T cell metabolism$647,057
R01 · FY2025 · CA · contact PI
Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturing$631,314
R01 · FY2025 · HL · contact PI
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$215,820
R01 · FY2025 · CA · contact PI
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$629,799
R01 · FY2024 · CA · contact PI
Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturing$618,687
R01 · FY2024 · HL · contact PI
Label-free imaging of CAR T cell metabolism$615,789
R01 · FY2024 · CA · contact PI
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$156,845
R01 · FY2024 · CA · contact PI
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$682,222
R01 · FY2023 · CA · contact PI
Label-free imaging of CAR T cell metabolism$662,022
R01 · FY2023 · CA · contact PI
Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturing$650,814
R01 · FY2023 · HL · contact PI
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging$247,962
R21 · FY2023 · EY · contact PI
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$611,987
U01 · FY2022 · EY
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging$232,173
R21 · FY2022 · EY · contact PI
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$611,987
U01 · FY2021 · EY
Optical imaging of pancreas cancer organoids for drug development and personalized treatment$554,862
R01 · FY2021 · CA · contact PI
Optical imaging of pancreas cancer organoids for drug development and personalized treatment$790,207
R01 · FY2020 · CA · contact PI
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$611,987
U01 · FY2020 · EY
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity$381,018
R01 · FY2020 · CA · contact PI
Optical imaging of pancreas cancer organoids for drug development and personalized treatment$611,452
R01 · FY2019 · CA · contact PI
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$602,712
U01 · FY2019 · EB
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity$369,626
R01 · FY2019 · CA · contact PI
Cellular level optical metabolic imaging to predict drug response in cancer$305,296
R01 · FY2019 · CA · contact PI
Optical imaging of pancreas cancer organoids for drug development and personalized treatment$246,397
R01 · FY2019 · CA · contact PI
3D biomimetic image-based stromal models of pancreatic cancer for drug screening$158,677
R21 · FY2019 · CA
Optical imaging of pancreas cancer organoids for drug development and personalized treatment$630,364
R01 · FY2018 · CA · contact PI
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$616,444
U01 · FY2018 · HL
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity$384,612
R01 · FY2018 · CA · contact PI
Cellular level optical metabolic imaging to predict drug response in cancer$314,739
R01 · FY2018 · CA · contact PI
3D biomimetic image-based stromal models of pancreatic cancer for drug screening$213,829
R21 · FY2018 · CA
Optical imaging of pancreas cancer organoids for drug development and personalized treatment$648,387
R01 · FY2017 · CA · contact PI
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity$388,402
R01 · FY2017 · CA · contact PI
Cellular level optical metabolic imaging to predict drug response in cancer$314,739
R01 · FY2017 · CA · contact PI
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity$406,070
R01 · FY2016 · CA · contact PI
Cellular level optical metabolic imaging to predict drug response in cancer$315,367
R01 · FY2015 · CA · contact PI
Cellular-level Optical Metabolic Imaging to Predict Drug Response in Cancer$315,367
R01 · FY2014 · CA · contact PI
Quantitative In Vivo Optical Imaging of Vascular Response to Hind Limb Ischemia$212,106
R21 · FY2013 · HL
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer$239,534
R00 · FY2012 · CA · contact PI
Quantitative In Vivo Optical Imaging of Vascular Response to Hind Limb Ischemia$183,800
R21 · FY2012 · HL
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer$240,321
R00 · FY2011 · CA · contact PI
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer$247,461
R00 · FY2010 · CA · contact PI
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer$88,596
K99 · FY2009 · CA · contact PI
Molecular optical coherence tomography for monitoring cancer therapy$18,049
F32 · FY2009 · CA · contact PI
Molecular optical coherence tomography for monitoring cancer therapy$46,826
F32 · FY2008 · CA · contact PI
Molecular optical coherence tomography for monitoring cancer therapy$44,846
F32 · FY2007 · CA · contact PI